INTRODUCTION
All-ScaleFlow™ – a revolutionary approach to the scale-up and production of mRNA-based vaccine and therapeutics
Dillico’s game-changing All-ScaleFlow™ technology offers an entirely new approach to mRNA-LNP manufacturing. All-ScaleFlow™ spells the end of multi-step scale-up and batch production processes, because it enables a single piece of equipment and one set of process parameters to manufacture any volume between 1,000 and 10 million doses. This simplifies and improves the development of mRNA vaccines and therapies, while removing major manufacturing roadblocks.
Dillico develops and markets an automated and digitized end-to-end mRNA-LNP continuous manufacturing solution tailored to its customers’ mRNA platforms.
Dillico’s global team of innovators, scientists and industry experts believes that continuous manufacturing can unlock the full potential of mRNA technology and reshape the biopharmaceutical industry landscape with next-generation therapeutics. This means improved global healthcare access, in particular for low- and medium-income countries combating regional diseases and emerging pandemics.
Dillico develops and markets an automated and digitized end-to-end mRNA-LNP continuous manufacturing solution tailored to its customers’ mRNA platforms.
Dillico’s global team of innovators, scientists and industry experts believes that continuous manufacturing can unlock the full potential of mRNA technology and reshape the biopharmaceutical industry landscape with next-generation therapeutics. This means improved global healthcare access, in particular for low- and medium-income countries combating regional diseases and emerging pandemics.
NEWS
Dillico moved
We are thrilled to announce that we are transitioning our site to a new location. As of now, we'll be located at Inovallée, Meylan; near our previous office in Grenoble. We’re heading to [...]
All-ScaleFlow™ Technology Presentation at Bioproduction Congress Lyon
The mRNA Revolution: During the pandemic, the implementation of mRNA technology was carried out at a record pace, utilizing existing manufacturing solutions developed for conventional vaccines. However, this approach came with its drawbacks [...]
Dillico Grand Prix i-Lab 2023
Dillico Grand Prix i-Lab 2023 (English version below) Nous sommes honorés d'avoir été choisis parmi de nombreux candidats exceptionnels, comme lauréat du Grand prix i-Lab 2023 ! Ce prix revêt une importance particulière car [...]